Literature DB >> 12859671

Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles.

Anurag Tandon1, Haung Yu, Linda Wang, Ekaterina Rogaeva, Christine Sato, M Azhar Chishti, Toshitaka Kawarai, Hiroshi Hasegawa, Fusheng Chen, Peter Davies, Paul E Fraser, David Westaway, Peter H St George-Hyslop.   

Abstract

Elevated levels of p25 and constitutive activation of CDK5 have been observed in AD brains. This has led to the hypothesis that increased p25 levels could promote neurofibrillary tangles (NFT) through CDK5-mediated hyperphosphorylation of tau, the principal component of NFTs. We examined p25 immunoreactivity in brains from sporadic and familial AD cases, as well as other neurologic diseases that exhibit NFT, such as Down's syndrome (DS), Pick's disease (Pick), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD). Neither the p25 immunoreactivity nor the p25/p35 ratio was elevated in the AD brains or in the other tauopathies (n = 34) compared with controls (n = 11). Although Abeta peptides have been suggested to activate calpain-mediated cleavage of p35 to p25 in cultured neurons, p25 levels in brains of TgCRND8 mice, which express high levels of brain Abeta peptides, were similar to those of non-Tg littermates. Our data suggest that high Abeta levels in brain do not activate p35 proteolysis, and p25 is unlikely to be a causative agent for NFT formation in AD or other tauopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859671     DOI: 10.1046/j.1471-4159.2003.01865.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  19 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.

Authors:  Yi Wen; W Haung Yu; Bryan Maloney; Jason Bailey; Junrong Ma; Isabelle Marié; Thomas Maurin; Lili Wang; Helen Figueroa; Mathieu Herman; Pavan Krishnamurthy; Li Liu; Emmanuel Planel; Lit-Fui Lau; Debomoy K Lahiri; Karen Duff
Journal:  Neuron       Date:  2008-03-13       Impact factor: 17.173

Review 3.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

4.  A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.

Authors:  Ya-Li Zheng; Sashi Kesavapany; Maneth Gravell; Rebecca S Hamilton; Manfred Schubert; Niranjana Amin; Wayne Albers; Philip Grant; Harish C Pant
Journal:  EMBO J       Date:  2004-12-09       Impact factor: 11.598

Review 5.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  PHF-like tau phosphorylation in mammalian hibernation is not associated with p25-formation.

Authors:  Jens Thorsten Stieler; Torsten Bullmann; Franziska Kohl; Brian M Barnes; Thomas Arendt
Journal:  J Neural Transm (Vienna)       Date:  2009-01-28       Impact factor: 3.575

7.  Activity-dependent p25 generation regulates synaptic plasticity and Aβ-induced cognitive impairment.

Authors:  Jinsoo Seo; Paola Giusti-Rodríguez; Ying Zhou; Andrii Rudenko; Sukhee Cho; Kristie T Ota; Christine Park; Holger Patzke; Ram Madabhushi; Ling Pan; Alison E Mungenast; Ji-Song Guan; Ivana Delalle; Li-Huei Tsai
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

Review 8.  Cdk5 activity in the brain - multiple paths of regulation.

Authors:  Kavita Shah; Debomoy K Lahiri
Journal:  J Cell Sci       Date:  2014-06-01       Impact factor: 5.285

9.  Relative resistance of Cdk5-phosphorylated CRMP2 to dephosphorylation.

Authors:  Adam R Cole; Marc P M Soutar; Makoto Rembutsu; Lidy van Aalten; C James Hastie; Hilary McLauchlan; Mark Peggie; Martin Balastik; Kun Ping Lu; Calum Sutherland
Journal:  J Biol Chem       Date:  2008-05-06       Impact factor: 5.157

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.